Regeneron Pharmaceuticals Cash Flow from Operations

REGN -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Regeneron Pharmaceuticals cash-flow-from-operations fundamental analysis lookup allows you to check this and other indicators for Regeneron Pharmaceuticals or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Regeneron Pharmaceuticals Cash Flow from Operations Analysis

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investor or analyst to check on the quality of a company earnings.
Operating Cash Flow 
More About Cash Flow from Operations | All Equity Analysis
Regeneron Pharmaceuticals Cash Flow from Operations  =
1.31 B
Regeneron Pharmaceuticals ValuationFundamentalsBuy or Sell

Regeneron Pharmaceuticals Cash Flow from Operations Over Time Pattern

 Regeneron Pharmaceuticals Net Cash Flow from Operations 

About Cash Flow from Operations

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about company having enough liquid resources to meet current and long term debt obligations.
Compare to competition

Regeneron Pharmaceuticals Cash Flow from Operations Assessment

Net Cash Flow from Operations
In accordance with recently published financial statements Regeneron Pharmaceuticals has 1.31 B in Cash Flow from Operations. This is 148.45% higher than that of the Healthcare sector, and 1995.17% higher than that of Biotechnology industry, The Cash Flow from Operations for all stocks is 34.88% lower than the firm.

Regeneron Pharmaceuticals Cash Flow from Operations Peer Comparison

  Cash Flow from Operations 
      Regeneron Pharmaceuticals Comparables 
Regeneron Pharmaceuticals is rated second in cash flow from operations category among related companies.

Regeneron Pharmaceuticals current financial ratios